Limited risk of drug resistance after discontinuation of antiretroviral prophylaxis for the prevention of breastfeeding transmission of HIV

Journal of Acquired Immune Deficiency Syndromes

Volumn 57, Issue 4, 2011, Pages 301-304

  Palombi, Leonardo ^a,b   Luhanga, Richard ^c   Galluzzo, Clementina ^d   Andreotti, Mauro ^d   Liotta, Giuseppe ^a,b   Ceffa, Susanna ^b   Haswell, Jere ^c   Marazzi, Maria Cristina ^e   Vella, Stefano ^d   Giuliano, Marina ^d  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b DREAM Program   (Italy)

^c DREAM Program   (Malawi)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e LUMSA UNIVERSITY   (Italy)

Author keywords

antiretroviral therapy; breastfeeding; HIV 1; mother tochild transmission; pregnancy; resistance

Indexed keywords

CD4 ANTIGEN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; VIRUS DNA; ZIDOVUDINE;

ADULT; ARTICLE; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; GESTATION PERIOD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; NONHUMAN; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; RASH; RISK ASSESSMENT; VIRUS LOAD;

ANTI-HIV AGENTS; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 79959953598     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318220ed92     Document Type: Article

References (12)

1. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal Transmission in the United States. May 24, 2010: 1-.117. Available at: http://aidsinfo.nih.gov/ContentFiles/perinatalGL.pdf. Accessed March 11, 2011.
2. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach. 2010 Version. Available at: http://www.who.int/hiv/pub/mtct/ antiretroviral2010/en/index.html. Accessed March 11, 2011.
3. Lockman S, Hughes H, McIntyre J, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med. 2010;363:1499-1509.
4. Fox Z, Phillips A, Cohen C, et al. Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS. 2008;22:2279-2289.
5. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med. 2009;17:138-145.
6. Palmisano L, Giuliano M, Bucciardini R, et al. Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions; The Istituto Superiore di Sanità-Pulsed Antiretroviral Therapy (ISS-PART) Study. J Acquir Immune Defic Syndr. 2007;46:39-47.
7. Lyons FE, Coughlan S, Byrne CM, et al. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS. 2005;19:63-67. (Pubitemid 40111019)
8. Paredes R, Cheng I, Kuritzkes DR, et al,Women and Infants Transmission Study (WITS) Group. Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy. AIDS. 2010;24:45-53.
9. Gingelmaier A, Eberle J, Kost BP, et al. Protease inhibitor-based antiretroviral prophylaxis during pregnancy and the development of drug resistance. Clin Infect Dis. 2010;50:890-894.
10. Pirillo M, Palmisano L, Pellegrini M, et al. Nonucleoside reverse transcriptase inhibitor concentrations during treatment interruptions and the emergence of resistance: a substudy of the ISS-PART trial. AIDS Res Hum Retrovir. 2010;26: 541-545.
11. Deeks S,Hoh R, Neilands TB, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis. 2005;192:1537-1544. (Pubitemid 41504689)
12. Chilton D, Dervisevic S, Pillay D, et al. Determinants of HIV drug resistance mutations in plasma virus after treatment interruptions. AIDS. 2005;19:2174-2175. (Pubitemid 41669010)